JP2017503756A5 - - Google Patents

Download PDF

Info

Publication number
JP2017503756A5
JP2017503756A5 JP2016533116A JP2016533116A JP2017503756A5 JP 2017503756 A5 JP2017503756 A5 JP 2017503756A5 JP 2016533116 A JP2016533116 A JP 2016533116A JP 2016533116 A JP2016533116 A JP 2016533116A JP 2017503756 A5 JP2017503756 A5 JP 2017503756A5
Authority
JP
Japan
Prior art keywords
muscle activity
treatment
deuterium
abnormal muscle
structural formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016533116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017503756A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/066740 external-priority patent/WO2015077520A1/en
Publication of JP2017503756A publication Critical patent/JP2017503756A/ja
Publication of JP2017503756A5 publication Critical patent/JP2017503756A5/ja
Pending legal-status Critical Current

Links

JP2016533116A 2013-11-22 2014-11-21 異常な筋活動を処置する方法 Pending JP2017503756A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907675P 2013-11-22 2013-11-22
US61/907,675 2013-11-22
PCT/US2014/066740 WO2015077520A1 (en) 2013-11-22 2014-11-21 Methods of treating abnormal muscular activity

Publications (2)

Publication Number Publication Date
JP2017503756A JP2017503756A (ja) 2017-02-02
JP2017503756A5 true JP2017503756A5 (2) 2018-01-11

Family

ID=53180159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016533116A Pending JP2017503756A (ja) 2013-11-22 2014-11-21 異常な筋活動を処置する方法

Country Status (8)

Country Link
US (1) US20160303110A1 (2)
EP (1) EP3071565A4 (2)
JP (1) JP2017503756A (2)
CA (1) CA2930167A1 (2)
HK (1) HK1224294A1 (2)
IL (1) IL245538A0 (2)
MX (1) MX2016006622A (2)
WO (1) WO2015077520A1 (2)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2015084622A1 (en) 2013-12-03 2015-06-11 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
EP2918266A1 (en) * 2014-03-11 2015-09-16 CDRD Berolina AB Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
AU2016229949B2 (en) 2015-03-06 2021-04-08 Auspex Pharmaceuticals Llc Methods for the treatment of abnormal involuntary movement disorders
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US10786202B2 (en) 2016-09-28 2020-09-29 International Business Machines Corporation Quantifying grip strength and characterizing movement idioms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7367953B2 (en) * 2003-11-26 2008-05-06 Ge Medical Systems Global Technology Company Method and system for determining a period of interest using multiple inputs
CA2642593C (en) * 2006-02-17 2014-11-04 Birds Pharma Gmbh Berolina Innovative Research & Development Services Deuterated catecholamine derivatives and medicaments comprising said compounds
CA2650904C (en) * 2006-05-02 2015-07-07 The Trustees Of The University Of Pennsylvania Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents
US8008500B2 (en) * 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
CN102056541B (zh) * 2008-06-12 2014-09-24 阿密格德勒有限公司 运动机能减退和/或运动机能亢进状态的检测
EP2318035B1 (en) * 2008-07-01 2019-06-12 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
CA2972242A1 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
EP3351247A1 (en) * 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2012006551A2 (en) * 2010-07-08 2012-01-12 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
US9901564B2 (en) * 2012-03-23 2018-02-27 Cardero Therapeutics, Inc. Compounds and compositions for the treatment of muscular disorders

Similar Documents

Publication Publication Date Title
JP2017503756A5 (2)
EP4663637A3 (en) Novel deuterium substituted positron emission tomography (pet) imaging agents and their pharmacological application
NZ721645A (en) Compounds for use as gpr120 agonists
BRPI0821994B8 (pt) composto ou um enantiômero, um diasteroisômero ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
RU2010145459A (ru) Ингибиторы активности протеинтирозинкиназы
JP2012526791A5 (2)
EA201590520A1 (ru) Фармацевтическая композиция с покрытием, содержащая регорафениб
JOP20180113B1 (ar) مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية
FI3738434T3 (fi) Välituotteita substituoitujen bentsaldehydiyhdisteiden saamiseksi ja menetelmiä niiden käyttöön kudosten hapetuksen lisäämiseksi
HRP20191617T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
JP2013032389A5 (2)
MY189770A (en) Biaryl derivative as gpr120 agonists
MX377202B (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
RU2008139315A (ru) Избирательные андрогенные рецепторные модуляторы
EP2681236A4 (en) METHOD FOR PRODUCING GUANYLATE CYCLASE C AGONISTS
MX2016007056A (es) Metodos para preparar compuestos de benzoquinolina.
EA201071099A1 (ru) СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
JP2014062126A5 (2)
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
BR112017020484A2 (pt) método para a fabricação de novo composto contendo nitrogênio ou sal do mesmo e intermediário de fabricação do novo composto contendo nitrogênio ou sal do mesmo
BR112018001534A2 (pt) inibidor de isocitrato desidrogenase idh1 r132h mutante
JP2017511377A5 (2)
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
BR112012017691A2 (pt) nova composição